NASDAQ:HSDT Helius Medical Technologies (HSDT) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free HSDT Stock Alerts $5.78 +0.08 (+1.40%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.53▼$5.8650-Day Range$4.41▼$7.7652-Week Range$4.29▼$14.44Volume9,354 shsAverage Volume450,841 shsMarket Capitalization$4.11 millionP/E RatioN/ADividend YieldN/APrice Target$54.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Helius Medical Technologies alerts: Email Address Helius Medical Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside842.1% Upside$54.50 Price TargetShort InterestHealthy4.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($17.04) to ($9.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.97 out of 5 stars 3.5 Analyst's Opinion Consensus RatingHelius Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.50, Helius Medical Technologies has a forecasted upside of 842.1% from its current price of $5.79.Amount of Analyst CoverageHelius Medical Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.34% of the float of Helius Medical Technologies has been sold short.Short Interest Ratio / Days to CoverHelius Medical Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Helius Medical Technologies has recently decreased by 39.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHelius Medical Technologies does not currently pay a dividend.Dividend GrowthHelius Medical Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HSDT. Previous Next 2.5 News and Social Media Coverage News SentimentHelius Medical Technologies has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Helius Medical Technologies this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HSDT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Helius Medical Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Helius Medical Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Helius Medical Technologies is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Helius Medical Technologies are expected to grow in the coming year, from ($17.04) to ($9.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Helius Medical Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Helius Medical Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHelius Medical Technologies has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Helius Medical Technologies Stock (NASDAQ:HSDT)Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.Read More HSDT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HSDT Stock News HeadlinesMarch 15, 2024 | globenewswire.comHelius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024March 12, 2024 | globenewswire.comHelius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in StrokeMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 11, 2024 | msn.comHelius Medical Technologies to Showcase Neurotech Innovations at the 36th Annual ROTH ConferenceMarch 9, 2024 | americanbankingnews.comRoth Capital Weighs in on Helius Medical Technologies, Inc.'s Q1 2024 Earnings (NASDAQ:HSDT)March 9, 2024 | americanbankingnews.comHelius Medical Technologies, Inc. Forecasted to Earn Q1 2024 Earnings of ($3.27) Per Share (NASDAQ:HSDT)March 7, 2024 | globenewswire.comHelius Medical Technologies, Inc. to Present at the 36th Annual ROTH ConferenceMarch 4, 2024 | marketwatch.comHelius Medical Shares Climb As PoNS Treatment Nears Reimbursement MilestoneMarch 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 4, 2024 | msn.comHelius Medical stock rallies 19% on CMS code assignmentsMarch 4, 2024 | msn.comWhy Is Neurotech-Focused Helius Medical Trading Higher On Monday?March 4, 2024 | globenewswire.comHelius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and ControllerFebruary 22, 2024 | investing.comHelius Medical Technologies Inc Class A (HSDT)February 7, 2024 | msn.comHelius Medical Technologies Amplifies Presence at 2024 APTA Combined Sections MeetingFebruary 6, 2024 | msn.comTraders Await Fresh Cues After Powell's Rate-Cut Commentary, Stifling US Equity Futures Pre-BellFebruary 6, 2024 | msn.comHelius Medical shares rally 25% on FDA meetingFebruary 6, 2024 | finance.yahoo.comHelius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke PatientsFebruary 5, 2024 | financialpost.comHelius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MSDecember 7, 2023 | finance.yahoo.comWall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should KnowDecember 7, 2023 | finance.yahoo.comWall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should KnowNovember 30, 2023 | finance.yahoo.comHelius Medical Technologies to Present at NobleCon19 Annual ConferenceNovember 28, 2023 | seekingalpha.comHSDT Helius Medical Technologies, Inc.November 13, 2023 | finance.yahoo.comHelius Medical Technologies, Inc. (NASDAQ:HSDT) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Helius Medical Technologies (HSDT)November 9, 2023 | finance.yahoo.comHelius Medical Technologies, Inc. Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comHelius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to WorkNovember 2, 2023 | finance.yahoo.comHelius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024See More Headlines Receive HSDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today3/18/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:HSDT CUSIPN/A CIK1610853 Webheliusmedical.com Phone(877) 564-0008FaxN/AEmployees26Year Founded2014Price Target and Rating Average Stock Price Target$54.50 High Stock Price Target$85.00 Low Stock Price Target$24.00 Potential Upside/Downside+842.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($21.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,070,000.00 Net Margins-1,602.40% Pretax Margin-1,602.40% Return on Equity-232.74% Return on Assets-100.23% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.61 Sales & Book Value Annual Sales$790,000.00 Price / Sales5.20 Cash FlowN/A Price / Cash FlowN/A Book Value$14.45 per share Price / Book0.40Miscellaneous Outstanding Shares710,000Free Float656,000Market Cap$4.11 million OptionableNot Optionable Beta1.41 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Dane Carl Andreeff (Age 58)President, CEO & Director Comp: $469.17kMr. Jeffrey S. Mathiesen CPA (Age 63)CFO, Treasurer, Secretary & Director Comp: $434.94kDr. Antonella Favit-Van Pelt M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $432.67kMr. Lawrence PiccianoSenior Vice President of Engineering, Quality & Regulatory AffairsKey CompetitorsBioSig TechnologiesNASDAQ:BSGMTivic Health SystemsNASDAQ:TIVCNuwellisNASDAQ:NUWEENDRA Life SciencesNASDAQ:NDRAAvingerNASDAQ:AVGRView All CompetitorsInsidersDane AndreeffBought 5,000 shares on 12/14/2023Total: $40,500.00 ($8.10/share)Dane AndreeffBought 2,000 shares on 11/30/2023Total: $12,740.00 ($6.37/share)Dane AndreeffBought 5,000 shares on 8/30/2023Total: $38,200.00 ($7.64/share)Dane AndreeffBought 5,078 shares on 8/28/2023Total: $32,346.86 ($6.37/share)View All Insider Transactions HSDT Stock Analysis - Frequently Asked Questions Should I buy or sell Helius Medical Technologies stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HSDT shares. View HSDT analyst ratings or view top-rated stocks. What is Helius Medical Technologies' stock price target for 2024? 1 Wall Street analysts have issued 1 year price objectives for Helius Medical Technologies' stock. Their HSDT share price targets range from $24.00 to $85.00. On average, they anticipate the company's share price to reach $54.50 in the next twelve months. This suggests a possible upside of 842.1% from the stock's current price. View analysts price targets for HSDT or view top-rated stocks among Wall Street analysts. How have HSDT shares performed in 2024? Helius Medical Technologies' stock was trading at $8.04 at the beginning of 2024. Since then, HSDT stock has decreased by 28.0% and is now trading at $5.7850. View the best growth stocks for 2024 here. Are investors shorting Helius Medical Technologies? Helius Medical Technologies saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 36,300 shares, a decline of 39.3% from the February 14th total of 59,800 shares. Based on an average daily volume of 297,100 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.3% of the company's shares are sold short. View Helius Medical Technologies' Short Interest. When is Helius Medical Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HSDT earnings forecast. How can I listen to Helius Medical Technologies' earnings call? Helius Medical Technologies will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Helius Medical Technologies' earnings last quarter? Helius Medical Technologies, Inc. (NASDAQ:HSDT) released its quarterly earnings data on Thursday, August, 10th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.50) by $2.50. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.17 million. Helius Medical Technologies had a negative trailing twelve-month return on equity of 232.74% and a negative net margin of 1,602.40%. During the same period last year, the business earned ($48.50) EPS. When did Helius Medical Technologies' stock split? Shares of Helius Medical Technologies reverse split before market open on Thursday, August 17th 2023. The 1-50 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Helius Medical Technologies? Shares of HSDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HSDT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helius Medical Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.